AnaptysBio to spin-off its biopharma and royalty management businesses.

AnaptysBio, a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, set to spin-off its biopharma and royalty management businesses. Financial terms were not disclosed. “In parallel with assessing multiple strategic options for rosnilimab in RA or UC, including securing a global partnership to help advance development in all indications or advancing in one Phase 3 indication independently, today’s announcement to explore a separation of our wholly owned biopharma programs from our royalty assets is intended to provide investors with the opportunity to realize and enhance the potential value of two distinct sets of assets,” Daniel Faga, Anaptys President and CEO.